Newsylist real-time news trend intelligence
▲ Peaking Business

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI is acquiring cancer genomics partner Personalis for $1.5 billion, though the announcement triggered a decline in share prices for both companies.

5sources
5articles
3velocity
+0%since first seen
6h agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

3210Jul 21 05:29Jul 21 13:29 UTC

The brief

Tempus AI has entered an agreement to acquire Personalis, a cancer test maker and genomics partner, in a deal valued at $1.5 billion. The acquisition aims to more tightly integrate molecular residual disease (MRD) capabilities into the AI-enabled precision oncology platform operated by Tempus.

Coverage from Reuters, Barron's, and Investor's Business Daily emphasizes the market's negative reaction, noting that shares for both companies sank following the news. Fierce Biotech and Business Wire highlight the strategic nature of the buyout regarding genomics and oncology integration.

Future developments depend on the finalization of the $1.5 billion deal and the subsequent integration of Personalis's technology into the Tempus AI platform.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6h ago.

Quick answers

How much is Tempus AI paying for Personalis?

The deal is valued at $1.5 billion.

What is the strategic goal of the acquisition?

Tempus intends to more tightly integrate molecular residual disease (MRD) into its AI-enabled precision oncology platform.

How did the stock market respond to the news?

Shares for both Tempus AI and Personalis dived or sank following the announcement.

Coverage (5)

People, places & organizations

Topics

Related trends